Compare TPCS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | NSRX |
|---|---|---|
| Founded | 1956 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 38.9M |
| IPO Year | 2008 | N/A |
| Metric | TPCS | NSRX |
|---|---|---|
| Price | $4.58 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 52.9K | 11.6K |
| Earning Date | 02-17-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.38 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,644,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.88 | $1.98 |
| 52 Week High | $6.25 | $9.99 |
| Indicator | TPCS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 48.82 |
| Support Level | $4.41 | $2.78 |
| Resistance Level | $4.71 | $3.60 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 18.97 | 43.70 |
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.